Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $850 million.

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.